A randomized trial of ex vivo CD40L activation of a dendritic cell vaccine in colorectal cancer patients: tumor-specific immune responses are associated with improved survival. Nov 2010 - Clin. Cancer Res.; 16(22):1078-0432 [PMID:20884622] [Barth RJ] [Fisher DA] [Wallace PK] [Channon JY] [Noelle RJ] [Gui J] [Ernstoff MS]
